3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solution
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedAbout 3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solution
3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solution is a phase 3 stage product being developed by Santen Pharmaceutical for Dry Eye. The current trial status is completed. This product is registered under clinical trial identifier NCT01240382. Target conditions include Dry Eye.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01240382 | Phase 3 | Completed |
Competing Products
20 competing products in Dry Eye
Other Products from Santen Pharmaceutical
Eybelis ophthalmic solution 0.002%Approved
85
Aflibercept Injection [Eylea]Approved
85
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Phase 3
77
DE-117B Eye Drops + LatanoprostPhase 3
77
DE-111 ophthalmic solution + Tafluprost ophthalmic solution 0.0015% + Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%Phase 3
77